4.5 Article

Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 73, Issue 7, Pages 924-930

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m07396

Keywords

-

Funding

  1. Pfizer
  2. National Alliance for Schizophrenia and Depression
  3. National Institute of Mental Health (NIMH)
  4. National Institute of Alcohol Abuse and Alcoholism
  5. Mayo Foundation
  6. AstraZeneca
  7. NIMH
  8. Sunovion
  9. Agency for Healthcare Research Quality
  10. Alkermes
  11. Cephalon
  12. Eli Lilly
  13. Forest Laboratories
  14. GlaxoSmithKline
  15. Jazz Pharmaceuticals
  16. Marriott Foundation
  17. Orodgen Therapeutics
  18. Shire
  19. Takeda Pharmaceutical
  20. Transcept Pharmaceutical
  21. Epi-Q
  22. Orexigen
  23. Netherlands Organisation for Health Research and Development
  24. European Union
  25. Stanley Medical Research Institute
  26. Wyeth
  27. Servier
  28. Medical Research Council, United Kingdom

Ask authors/readers for more resources

Objective:The long-term impact of prior antidepressant exposure on the subsequent course of bipolar illness remains controversial. Method: 139 outpatients (mean age, 42 years) with bipolar I disorder diagnosed by DSM-IV criteria had a detailed retrospective examination of their prior course of illness on the National Institute of Mental Health Life Chart Method. Number of prior antidepressant trials and total duration of antidepressant exposure were assessed. Prospective long-term response (for at least 6 months) to naturalistic treatment in the network from 1996 through 2002 was the primary outcome measure as it related to prior antidepressant exposure (and other illness variables) by logistic regression, with P < .05 used for statistical significance in this post hoc analysis. Results: Greater number of antidepressant trials, but not duration of antidepressant exposure, was related to prospective nonresponse (P=.0051) whether or not antidepressants were covered by concurrent treatment with a mood stabilizer or atypical antipsychotic. Poor prospective response was also independently related to having had an anxiety disorder and 20 or more prior affective episodes. Conclusions: That the number of antidepressant trials, but not duration of antidepressant treatment, was associated with prospective nonresponse suggests that it is the repeated use of antidepressants to treat episodes of depression that is related to poor prospective response to naturalistic treatment. The direction of causality is unclear as to whether more antidepressant trials led to this increased treatment resistance or whether a difficult course of illness with more episodes and anxiety comorbidity engendered more attempts at antidepressant treatment. J Clin Psychiatry 2012;73(7):924-930 (c) Copyright 2012 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review

Eva Z. Reininghaus, Mirko Manchia, Nina Dalkner, Nina Bonkat, Alessio Squassina, Isabel Hodl, Eduard Vieta, Andreas Reif, Tomas Hajek, Mikael Landen, Christoph U. Correll, Jan Scott, Bruno Etain, Marcella Rietschel, Veerle Bergink, Monica Martinez-Cengotitabengoa, Lars Vedel Kessing, Andrea Fagiolini, Michael Bauer, Guy Goodwin, Ana Gonzalez-Pinto, Ralph W. Kupka, Thomas G. Schulze, Trine Lagerberg, Aysegul Yildiz, Chantal Henry, Gunnar Morken, Phillip Ritter, Rene Ernst Nieslen, Rasmus W. Licht, Andreas Bechdolf, Ole A. Andreassen, Frederike Tabea Fellendorf

Summary: Patients with bipolar disorder may have a higher risk of contracting COVID-19, leading to worsened clinical outcomes. However, research on vaccination in individuals with BD is limited and lacks substantial evidence.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Article Clinical Neurology

Clinical profiles of subsequent stages in bipolar disorder: Results from the Dutch Bipolar Cohort

Afra van der Markt, Ursula M. H. Klumpers, Annemiek Dols, Marco P. Boks, Annabel Vreeker, Aartjan T. F. Beekman, Ralph W. Kupka

Summary: This study aimed to identify a combination of clinical characteristics associated with progression in two clinical staging models for bipolar disorder. The results showed that factors such as familial loading, childhood abuse, earlier onset, longer illness duration, psychiatric comorbidity, and treatment resistance were predictors for a higher stage in the progression of the disorder.

BIPOLAR DISORDERS (2022)

Article Geriatrics & Gerontology

Is social functioning in older age patients with bipolar disorder associated with affective and/or non-affective cognition?

Nadine P. G. Paans, Nicole Korten, Melis Orhan, Anne Ensing, Sigfried N. T. M. Schouws, Ralph Kupka, Patricia van Oppen, Annemiek Dols

Summary: Previous research has shown that non-affective cognition is positively associated with social functioning in adult patients with bipolar disorder (BD), while the association between affective cognition and social functioning is not significant. However, there is an interaction between non-affective and affective cognition.

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2022)

Editorial Material Clinical Neurology

A historical perspective on illness progression in bipolar disorder

Afra van der Markt, Ursula Klumpers, Annemiek Dols, Aartjan Beekman, Edward Shorter, Ralph Kupka

BIPOLAR DISORDERS (2022)

Review Pharmacology & Pharmacy

The pharmacotherapeutic management of comorbid bipolar disorder and alcohol use disorder

Heinz Grunze, Michael Soyka

Summary: This paper explores the available pharmacotherapies for AUD, BD, and their potential utility in comorbid BD and AUD. It also touches on the epidemiology, diagnosis, and common neurobiological traits of comorbid BD and AUD to some extent.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Article Clinical Neurology

Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs

Miriam von Mucke Similon, Cecilia Paasche, Fas Krol, Bernard Lerer, Guy M. Goodwin, Michael Berk, Andreas Meyer-Lindenberg, Terence A. Ketter, Lakshmi N. Yatham, Joseph F. Goldberg, Gin S. Malhi, Rif El-Mallakh, Rasmus W. Licht, Allan H. Young, Flavio Kapczinski, Marnina Swartz, Michal Hagin, Carla Torrent, Alessandro Serretti, Aysegul Yildiz, Anabel Martinez-Aran, Sergio Strejilevich, Janusz Rybakowski, Gabriele Sani, Heinz Grunze, Gustavo Vazquez, Ana Gonzales Pinto, Jean Michel Azorin, Willem Nolen, Othman Sentissi, Carlos Lopez-Jaramillo, Benicio N. Frey, Andrew Nierenberg, Gordon Parker, David J. Bond, Adam Cohen, Alfonso Tortorella, Giulio Perugi, Eduard Vieta, Dina Popovic

Summary: This study provides consensus recommendations for the selection of clinical trial design in psychiatry by surveying clinical and academic experts. The expert panel achieved consensus on 7 out of 21 recommendations regarding the use of randomized clinical trials, strongly supporting their use.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2022)

Article Psychiatry

The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management

Roger S. McIntyre, Martin Aida, Ross J. Baldessarini, Michael Bauer, Michael Berk, Christoph U. Correll, Andrea Fagiolini, Kostas Fountoulakis, Mark A. Frye, Heinz Grunze, Lars Kessing, David J. M. Iklowitz, Gordon Parker, Robert M. Post, Alan C. Swann, Trisha Suppes, Eduard Vieta, Allan Young, Mario Maj

Summary: This paper aims to synthesize the clinical characteristics of patients with bipolar disorder to improve their health outcomes and treatment choices. Existing data indicate that certain features of bipolar disorder are associated with illness trajectory, treatment response, and suicide risk. Early environmental exposure is also related to the complexity of the illness.

WORLD PSYCHIATRY (2022)

Article Clinical Neurology

Course of subthreshold manic symptoms and related risk factors in the general population: A three-year follow-up study

Rosalie A. L. Beekman, Margreet ten Have, Ron de Graaf, Ralph W. Kupka, Eline J. Regeer

Summary: This study examines the characteristics, course, and risk factors for an unfavourable course of subthreshold manic symptoms (subM), which are a risk factor for bipolar disorder. The study found that subM had a three-year prevalence of 4.9% and that 25.0% of individuals with subM had persistent symptoms and 6.1% transitioned to full manic episodes. The study also identified 11 risk factors for an unfavourable course, including a history of depression, living alone, and elevated neuroticism score.

BIPOLAR DISORDERS (2023)

Article Clinical Neurology

Bipolar I and bipolar II subtypes in older age: Results from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) project

Alexandra J. M. Beunders, Federica Klaus, Almar A. L. Kok, Sigfried N. T. M. Schouws, Ralph W. Kupka, Hilary P. Blumberg, Farren Briggs, Lisa T. Eyler, Brent P. Forester, Orestes Forlenza, Ariel Gildengers, Esther Jimenez, Benoit H. Mulsant, Regan E. Patrick, Soham Rej, Martha Sajatovic, Kaylee Sarna, Ashley Sutherland, Joy Yala, Eduard Vieta, Luca M. Villa, Nicole C. M. Korten, Annemieke Dols

Summary: This study compared bipolar I disorder (BD-I) and bipolar II disorder (BD-II) in a large, global sample and found no significant differences between the two in terms of general functioning, cognition, and somatic burden. These findings suggest that the distinction between BD-I and BD-II may not be applicable to geriatric bipolar disorder patients.

BIPOLAR DISORDERS (2023)

Review Psychiatry

The detrimental effects of smoking on the course and outcome in adults with bipolar disorder-A narrative review

Anna Grunze, Sergey Mosolov, Heinz Grunze, Christoph Born

Summary: This narrative review examines the epidemiology, consequences, and treatment options of tobacco use disorder (TUD) and nicotine dependence (ND) in individuals with bipolar disorder (BD). The study found that smoking rates are 2-3 times higher in individuals with BD compared to community samples. Smoking has a detrimental impact on both mental and physical health as well as mortality in individuals with BD. Treatment options include pharmacological interventions and psychosocial interventions.

FRONTIERS IN PSYCHIATRY (2023)

Article Clinical Neurology

A multicomponent positive psychology intervention for euthymic patients with bipolar disorder to improve mental well-being and personal recovery: A pragmatic randomized controlled trial

Jannis T. Kraiss, Peter M. ten Klooster, Melissa Chrispijn, Anja Stevens, Bennard Doornbos, Ralph W. Kupka, Ernst T. Bohlmeijer

Summary: This study evaluated the effectiveness of a multicomponent positive psychology intervention (PPI) as an adjunct to treatment for euthymic patients with bipolar disorder (BD). The results showed that the PPI group had significantly improved mental well-being and personal recovery compared to the group that received only usual treatment. Therefore, this intervention method is valuable for the treatment of euthymic BD patients.

BIPOLAR DISORDERS (2023)

Article Clinical Neurology

Development and validation of a Manic Thought Inventory

Imke Hanssen, Peter ten Klooster, Marloes Huijbers, Marc Lochmann van Bennekom, Elvira Boere, Ebtisam El Filali, Bart Geerling, Peter Goossens, Ralph Kupka, Anne Speckens, Eline Regeer

Summary: This article presents the development and psychometric evaluation of the Manic Thought Inventory (MTI), a self-report inventory designed to assess the presence of typical (hypo)manic cognitions. Results from two studies demonstrate that the MTI has good psychometric properties and can be valuable in both research and clinical practice.

BIPOLAR DISORDERS (2023)

Editorial Material Clinical Neurology

Measuring serum concentrations of psychotropics- Valuable tool for decision making or waste of money?

Heinz Grunze

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder

Heinz Grunze

Summary: The comorbidity of substance use disorder with schizophrenia significantly increases morbidity and mortality compared to schizophrenia alone. Dopaminergic dysregulation appears to be a common pathophysiological basis of this comorbidity. Cariprazine, a partial agonist of D3 and D2 dopamine receptors, shows promising results in early clinical observations for the therapy of dual disorder.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Article Psychology, Clinical

Accelerated brain aging as a biomarker for staging in bipolar disorder: an exploratory study

Afra van der Markt, Ursula Klumpers, Annemiek Dols, Nicole Korten, Marco P. Boks, Roel A. Ophoff, Aartjan Beekman, Ralph Kupka, Neeltje E. M. van Haren, Hugo Schnack

Summary: This study investigates the association between brain structures and illness progression in bipolar disorder (BD) and explores the potential of brain-predicted age difference (brain-PAD) as a biomarker for BD staging. The results suggest that higher brain-PAD is associated with impaired inter-episodic functioning, but this association loses significance after considering confounding factors such as lithium-use and comorbid anxiety disorders. There is no significant association between global and (sub)cortical brain measures and illness stages.

PSYCHOLOGICAL MEDICINE (2023)

No Data Available